Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy

This publication has 52 references indexed in Scilit:

• Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
  British Journal of Cancer, 2013
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
  New England Journal of Medicine, 2012
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
  Current Opinion in Immunology, 2012
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
  Science Translational Medicine, 2012
• Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
  Blood, 2010
• PD-1 and Its Ligands in Tolerance and Immunity
  Annual Review of Immunology, 2008
• Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
  Journal of Virology, 2007
• Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma
  American Journal of Surgical Pathology, 2006
• Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications inDe novoAcute Myeloid Leukemia
  Clinical Cancer Research, 2005
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
  Journal of Experimental Medicine, 2003